Summary: In an article featuring the perspective of MAPS Founder and Executive Director Rick Doblin, Ph.D., ABC News covers MAPS’ efforts to make MDMA-assisted therapy for PTSD a legal prescription medicine, focusing primarily on the successful results of the Phase 3 clinical trial of MDMA-assisted therapy for PTSD, which was sponsored by MAPS and published last week in Nature Medicine. Doblin cautions, however, that although the historic study is now published, “the hardest parts are still ahead.”
Originally appearing here.
